Literature analysis of semaglutide-induced adverse drug reaction

SUN Runan; CANG Daixiao; QUAN Xianghua; ZHANG Chuanzhou; ZHAO Jun

doi:10.6039/j.issn.1001-0408.2024.18.13

您当前的位置：

首页 >

文章列表页 >

Literature analysis of semaglutide-induced adverse drug reaction

更新时间：2024-09-25

- Literature analysis of semaglutide-induced adverse drug reaction
- ZHONGGUO YAOFANG Vol. 35, Issue 18, Pages: 2266-2271(2024)
- 作者机构：
  
  1.青岛大学附属医院药学部，山东青岛　266003
  2.潍坊市妇幼保健院药学部，山东潍坊　261000
  3.临沭县中医医院药剂科，山东临沂　276700
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2024.18.13
  CLC： R969.3;R977.1+5
- Published：30 September 2024，
  
  Received：26 April 2024，
  
  Revised：24 July 2024，
- 稿件说明：
移动端阅览
孙如男,仓代晓,全香花等.司美格鲁肽致药品不良反应文献分析 ^Δ[J].中国药房,2024,35(18):2266-2271.

SUN Runan,CANG Daixiao,QUAN Xianghua,et al.Literature analysis of semaglutide-induced adverse drug reaction[J].ZHONGGUO YAOFANG,2024,35(18):2266-2271.
孙如男,仓代晓,全香花等.司美格鲁肽致药品不良反应文献分析 ^Δ[J].中国药房,2024,35(18):2266-2271. DOI： 10.6039/j.issn.1001-0408.2024.18.13.

SUN Runan,CANG Daixiao,QUAN Xianghua,et al.Literature analysis of semaglutide-induced adverse drug reaction[J].ZHONGGUO YAOFANG,2024,35(18):2266-2271. DOI： 10.6039/j.issn.1001-0408.2024.18.13.

摘要

目的

探讨司美格鲁肽致药品不良反应（ADR）的特点，为其临床安全应用提供参考。

方法

以“司美格鲁肽”“不良反应”等的中英文为检索词，检索PubMed、Web of Science、SpringerLink、中国知网、中华医学期刊全文数据库、万方医学网及维普医药信息资源系统，收集司美格鲁肽致ADR的病例报道并进行分析。

结果

共纳入14篇文献，共计17例患者。17例患者中，女性9例、男性8例，年龄25～80岁；8例患者合并应用2种及2种以上药物；8例患者以0.25 mg为起始剂量；大多ADR（94.12%）发生在用药后6个月内；16例患者经停药和/或对症治疗后均好转或痊愈；11例患者未提及后续是否继续使用司美格鲁肽；9例患者进行了ADR相关性评价，断定为“肯定”“很可能”“可能”“有可能”的分别有1、3、1、4例。司美格鲁肽致ADR可累及多个器官或系统，以消化系统最多（35.29%），其次为皮肤组织（29.41%）；其中，急性胃扩张、重度肝损伤、结石性胆囊炎、大疱性类天疱疮、嗜酸性筋膜炎、急性肾损伤、急性间质性肾炎、抑郁症、急性溶血性贫血均为药品说明书未记载的ADR。

结论

司美格鲁肽所致ADR可发生在各年龄段，以用药后6个月内发生为主，主要累及消化系统、皮肤组织等。临床使用时，应重点加强对肝肾功能不全、神经精神疾病、葡萄糖-6-磷酸脱氢酶缺乏症等人群的药学监护，出现相关ADR时应及时停药和/或对症治疗，以保障患者的用药安全。

Abstract

OBJECTIVE

To explore the characteristics of adverse drug reaction （ADR） induced by semaglutide and provide a reference for clinically safe medication.

METHODS

Using search terms such as “semaglutide” and “adverse reactions” in both Chinese and English， the case reports about ADRs caused by semaglutide were searched and analyzed from PubMed， Web of Science， SpringerLink， CNKI， Chinese Medical Journal Full-text Database， Wanfang Medical Network and VMIS.

RESULTS

Overall 14 literature were included， involving 17 patients. Among 17 patients， 9 were female and 8 were male， with the age ranging from 25 to 80 years. Eight patients were given two or more drugs， and eight patients took 0.25 mg as the initial dose； the ADR occurred most frequently within 6 months （94.12%）. Sixteen patients’ symptoms improved or recovered after drug withdrawal and symptomatic treatment. Eleven patients did not mention whether to continue to use semaglutide in the future. Nine patients underwent ADR correlation evaluation， and 1， 3， 1 and 4 cases were determined to be “definite”， “probable”， “possible”， and “doubtful” respectively. Semaglutide-induced ADRs involved multiple organs or systems， most of which were the digestive system （35.29%）， followed by skin tissue （29.41%）. Among them， acute gastric dilation， severe liver injury， calculous cholecystitis， bullous pemphigoid， eosinophilic fasciitis， acute kidney injury， acute interstitial nephritis， depression and acute hemolytic anemia were not mentioned in the instruction.

CONCLUSIONS

ADRs caused by semaglutide can occur in all ages， mainly within 6 months after medication， and mainly involve the digestive system， skin tissue， etc. Great attention should be paid to pharmaceutical care for those patients with liver and kidney dysfunction， neuropsychiatric diseases， glucose-6-phosphate dehydrogenase deficiency， etc. When ADR occurs， drug withdrawal and symptomatic treatment should be performed promptly to ensure patients’ medication safety.

关键词

司美格鲁肽不良反应病例报道文献分析

Keywords

adverse drug reactioncase reportliterature analysis

references

王思骅，汪盛，王岩，等. 司美格鲁肽治疗2型糖尿病的快速卫生技术评估[J]. 中国药房，2023，34（12）：1503-1508.

WANG S H，WANG S，WANG Y，et al. Semaglutide in the treatment of type 2 diabetes mellitus：rapid health technology assessment[J]. China Pharm，2023，34（12）：1503-1508.

司海娇，肇丽梅，蔡爽，等. 胰高血糖素样肽1受体激动剂类药物用药指导：2023版[J]. 中国药房，2023，34（11）：1281-1292.

SI H J，ZHAO L M，CAI S，et al. Medication guidelines for glucagon-like peptide-1 receptor agonist：2023 edition[J]. China Pharm，2023，34（11）：1281-1292.

张婷婷，吴红花，张俊清. 司美格鲁肽临床应用有效性和安全性与剂量关系的研究进展[J]. 中华医学杂志，2023，103（35）：2828-2832.

ZHANG T T，WU H H，ZHANG J Q. Research progress on the relationship between clinical efficacy，safety and dose of smeagoutide[J]. Natl Med J China，2023，103（35）：2828-2832.

RUBINO D M，GREENWAY F L，KHALID U，et al. Effect of weekly subcutaneous semaglutide vs daily lira-glutide on body weight in adults with overweight or obesity without diabetes：the STEP 8 randomized clinical trial[J]. JAMA，2022，327（2）：138-150.

SANZ SEGURA P，ARGUEDAS LÁZARO Y，MOSTACERO TAPIA S，et al. Acute gastric dilation associated with the use of semaglutide，a GLP-1 analogue[J]. Gastroenterol Hepatol，2022，45（Suppl. 1）：125-126.

LEEHEY D J，RAHMAN M A，BORYS E，et al. Acute kidney injury associated with semaglutide[J]. Kidney Med，2021，3（2）：282-285.

BURRUSS C P，JONES J M，BURRUSS J B. Semaglutide-associated bullous pemphigoid[J]. JAAD Case Rep，2021，15：107-109.

HEARN E B，SHERMAN J J. Injection-site nodules as-sociated with once-weekly subcutaneous administration of semaglutide[J]. Diabetes Spectr，2021，34（1）：73-75.

秦桂兰，周木子，冀召帅，等. 司美格鲁肽注射液致急性便秘1例分析[J]. 中国药物警戒，2023，20（7）：833-835.

QIN G L，ZHOU M Z，JI Z S，et al. One case of acute constipation induced by semaglutide injection[J]. Chin J Pharmacovigil，2023，20（7）：833-835.

殷欢莉，于磊，苏兰，等. 司美格鲁肽注射液致重度肝损伤[J]. 药物不良反应杂志，2023，25（12）：763-765.

YIN H L，YU L，SU L，et al. Severe liver injury caused by semaglutide injection[J]. Adverse Drug React J，2023，25（12）：763-765.

BORKUM M，LAU W，BLANCO P，et al. Semaglutide-associated acute interstitial nephritis：a case report[J]. Kidney Med，2022，4（12）：100561.

张卫，蒋志涛，李杰. 司美格鲁肽注射液致结石性胆囊炎一例[J]. 临床药物治疗杂志，2023，21（9）：90-92.

ZHANG W，JIANG Z T，LI J. Calculous cholecystitis caused by semaglutide injection：a case report[J]. Clin Med J，2023，21（9）：90-92.

HEERSPINK H J L，APPERLOO E，DAVIES M，et al. Effects of semaglutide on albuminuria and kidney fun-ction in people with overweight or obesity with or without type 2 diabetes：exploratory analysis from the STEP 1，2，and 3 trials[J]. Diabetes Care，2023，46（4）：801-810.

KLEIN S R，HOBAI I A. Semaglutide，delayed gastric emptying，and intraoperative pulmonary aspiration：a case report[J]. Can J Anaesth，2023，70（8）：1394-1396.

PATEL F，GAN A，CHANG K R，et al. Acute pancreatitis in a patient taking semaglutide[J]. Cureus，2023，15（8）：e43773.

OUELLETTE S，FRIAS G，SHAH R，et al. Dermal hypersensitivity reaction to semaglutide：two case reports[J]. J Drugs Dermatol，2023，22（4）：413-416.

SALEH A K，AL SALEH M M，ALBAQAR O A，et al. Acute hemolytic anemia following semaglutide injection：a case report[J]. Middle East J Fam Med，2022，20（12）：139.

LI J R，CAO J Y，WEI J，et al. Case Report：Semaglutide-associated depression：a report of two cases[J]. Front Psychiatry，2023，14：1238353.

CHAO A M，TRONIERI J S，AMARO A，et al. Sema-glutide for the treatment of obesity[J]. Trends Cardiovasc Med，2023，33（3）：159-166.

FLINT A，ANDERSEN G，HOCKINGS P，et al. Randomised clinical trial：semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging[J]. Aliment Pharmacol Ther，2021，54（9）：1150-1161.

ZHU K，KAKKAR R，CHAHAL D，et al. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease[J]. World J Gastroenterol，2023，29（37）：5327-5338.

GETHER I M，NEXØE-LARSEN C，KNOP F K. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs[J]. J Clin Endocrinol Metab，2019，104（7）：2463-2472.

李鑫，张蔚，王睿韬. 胰高血糖素样肽-1受体激动剂致2型糖尿病患者不良反应文献分析[J]. 临床合理用药，2024，17（5）：14-19.

LI X，ZHANG W，WANG R T. Literature analysis of adverse reactions induced by GLP-1RA in patients with type 2 diabetes mellitus[J]. Chin J Clin Ration Drug Use，2024，17（5）：14-19.

SMITS M M，VAN RAALTE D H. Safety of semaglutide[J]. Front Endocrinol，2021，12：645563.

MITCHELL P D，SALTER B M，OLIVERIA J P，et al. Glucagon-like peptide-1 receptor expression on human eosinophils and its regulation of eosinophil activation[J]. Clin Exp Allergy，2017，47（3）：331-338.

AVILES BUENO B，SOLER M J，PEREZ-BELMONTE L，et al. Semaglutide in type 2 diabetes with chronic kidney disease at high risk progression-real-world clinical practice[J]. Clin Kidney J，2022，15（8）：1593-1600.

匡彬. 引起慢性肾功能不全急性加重原因临床分析[J]. 当代医学，2010，16（16）：41-42.

KUANG B. Clinical analysis of the causes of acute exacer-bation of chronic renal insufficiency[J]. Contemp Med，2010，16（16）：41-42.

KIM Y K，KIM O Y，SONG J. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation，neurotransmitters，neurogenesis，and synaptic function[J]. Front Pharmacol，2020，11：1270.

TSAI W H，SUNG F C，CHIU L T，et al. Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist：a nationwide，population-based cohort study[J]. Front Pharmacol，2022，13：765446.

GUIRGUIS A，CHIAPPINI S，PAPANTI P G D，et al. Exploring the association between suicidal thoughts，self-injury，and GLP-1 receptor agonists in weight loss treatments：insights from pharmacovigilance measures and unmasking analysis[J]. Eur Neuropsychopharmacol，2024，82：82-91.

RUGGIERO R，MASCOLO A，SPEZZAFERRI A，et al. Glucagon-like peptide-1 receptor agonists and suicidal ideation：analysis of real-world data collected in the European pharmacovigilance database[J]. Pharmaceuticals，2024，17（2）：147.

CHIAPPINI S，VICKERS-SMITH R，HARRIS D，et al. Is there a risk for semaglutide misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System（FAERS）pharmacovigilance dataset[J]. Pharmaceuticals，2023，16（7）：994.

REDDY I A，PINO J A，WEIKOP P，et al. Glucagon-like peptide 1 receptor activation regulates cocaine actions and dopamine homeostasis in the lateral septum by decreasing arachidonic acid levels[J]. Transl Psychiatry，2016，6（5）：e809.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Renal injury caused by tenofovir disoproxil fumarate in a patient with liver cancer complicated with HBV infection： a case report and literature analysis

Pharmaceutical care for one case of levofloxacin-induced hypersensitivity reaction by the participation of clinical pharmacists and literature analysis

Literature analysis of atypical fractures associated with denosumab

Literature analysis of ocular adverse drug reactions related to dupilumab

Literature analysis of sunitinib-induced nephrotic syndrome

Related Author

CHANG Yingying

LIU Jiyong

WANG Feng

CAO Lei

QIN Zhou

YIN Huanli

HUANG Yuezhou

LUO Min

Related Institution

Dept. of Clinical Oncology， Shanghai Medical College of Fudan University

Dept. of Pharmacy， Fudan University Shanghai Cancer Center

Dept. of Clinical Pharmacy， West China Hospital of Sichuan University

Dept. of Pharmacy， Zhengzhou Orthopaedic Hospital

Dept. of Pharmacy， Medical Supplies Center of PLA General Hospital

Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰